---
title: "LGND.US (LGND.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LGND.US/news.md"
symbol: "LGND.US"
name: "LGND.US"
parent: "https://longbridge.com/en/quote/LGND.US.md"
datetime: "2026-05-20T06:54:28.482Z"
locales:
  - [en](https://longbridge.com/en/quote/LGND.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LGND.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LGND.US/news.md)
---

# LGND.US (LGND.US) — Related News

### [Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company](https://longbridge.com/en/news/286776618.md)
*2026-05-18T13:03:02.000Z*
> Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings as a party. T

### [Ligand Pharmac-B | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M](https://longbridge.com/en/news/285771751.md)
*2026-05-08T20:22:25.000Z*
### [Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives](https://longbridge.com/en/news/285651281.md)
*2026-05-08T02:12:51.000Z*
> Ligand Pharmaceuticals (LGND) reported Q1 2026 revenue of $51.7 million with a basic EPS loss of $0.67, contrasting with

### [Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down  After Earnings Miss](https://longbridge.com/en/news/285570474.md)
*2026-05-07T14:20:52.000Z*
> Ligand Pharmaceuticals (NASDAQ:LGND) shares gapped down to $205.00 after reporting disappointing earnings, missing EPS e

### [](https://longbridge.com/en/news/285393708.md)
*2026-05-06T13:15:17.000Z*
> United Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

### [Ligand Pharmac-B | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 51.72 M](https://longbridge.com/en/news/285536409.md)
*2026-05-07T11:08:11.000Z*
### [14:55 ETAre XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/285107937.md)
*2026-05-04T18:55:38.000Z*
> Halper Sadeh LLC is investigating XOMA, RMAX, and KALV for potential violations of federal securities laws and breaches